Nuo Therapeutics, Inc. (AURX)
| Market Cap | 60.36M |
| Revenue (ttm) | 2.61M |
| Net Income (ttm) | -2.43M |
| Shares Out | 48.29M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,346 |
| Average Volume | 5,566 |
| Open | 1.300 |
| Previous Close | 1.400 |
| Day's Range | 1.150 - 1.300 |
| 52-Week Range | 1.000 - 3.230 |
| Beta | -926.26 |
| RSI | 30.64 |
| Earnings Date | Apr 1, 2026 |
About Nuo Therapeutics
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and ch... [Read more]
Financial Performance
In 2024, Nuo Therapeutics's revenue was $1.37 million, an increase of 124.34% compared to the previous year's $608,525. Losses were -$2.32 million, -26.73% less than in 2023.
Financial StatementsNews
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging...
Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chro...
Nuo Therapeutics Selected to Exhibit Aurix® System at Vizient Innovative Technology Exchange
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging ...
Nuo Therapeutics' Aurix® System Added To Wound Care Formulary Of Wound Care Advantage
HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging ...
Nuo Therapeutics Provides Corporate and Business Update
Broad equity incentive agreement established with Pacific Medical, Inc. including initial equity purchase